calendar
32 catalysts · 4,207 phase readout · 2,234 8k filing · 282 earnings · 172 phase 2 completion · 93 drug shortage · 73 phase 1 completion
next 91 dayslessmore
MonWedFri
32 catalysts · 4,207 phase readout · 2,234 8k filing · 282 earnings · 172 phase 2 completion · 93 drug shortage · 73 phase 1 completion
Sponsor: EXTROVIS. Form: SOLUTION. Route: INTRAVENOUS
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: QUAGEN. Form: SYRUP. Route: ORAL
Sponsor: YICHANG HUMANWELL. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: GLENMARK SPECLT. Form: CREAM. Route: TOPICAL
Sponsor: MARKSANS PHARMA. Form: CAPSULE, DELAYED RELEASE. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL
Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL
AI grant. $209,758. PI: Paul K Drain
AT grant. $601,259. PI: Ashley E. Mason
NS grant. $568,920. PI: Theresa Currier Thomas
CA grant. $496,357. PI: DANIEL J BRAT
AT grant. $170,640. PI: Julia E. Hooker
AI grant. $210,302. PI: William Evan Johnson
DK grant. $231,000. PI: Roger D. Cone
NS grant. $230,562. PI: Thuy Nguyen
ES grant. $117,747. PI: Rebecca Sugrue
Sponsor: AUROBINDO PHARMA LTD. Form: TABLET. Route: ORAL
Therapy area: Infectious Disease. Indication: Pulmonary Tuberculosis
Sponsor: ABBVIE. Form: IMPLANT. Route: INTRAVITREAL
Sponsor: ACCORD HLTHCARE. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: AUROBINDO PHARMA. Form: CAPSULE. Route: ORAL
Therapy area: Oncology, Undisclosed. Indication: Lung Cancer, Solid Tumor, Unspecified Rare Disease
Therapy area: Dermatology. Indication: Diabetic Foot Ulcers
Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)
Therapy area: Cardiovascular, Dermatology, Infectious Disease, Respiratory. Indication: Anthrax, Bacteremia, Bacterial Endocarditis, Bacterial Pneumonia, Complicated Skin And Skin Structure Infections (cSSSI), Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, Hospital Acquired Pneumonia (HAP), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Skin And Soft Tissue Infections, Ventilator Associated Pneumonia (VAP)
Sponsor: NOVARTIS. Form: TABLET. Route: ORAL